Predicted to have DNA-binding transcription activator activity, RNA polymerase II-specific; RNA polymerase II cis-regulatory region sequence-specific DNA binding activity; and histone deacetylase binding activity. Involved in prostate gland development; response to estrogen; and response to testosterone. Predicted to localize to cytoplasm; nucleus; and transcription regulator complex. Orthologous to human HOXA10 (homeobox A10); INTERACTS WITH 17beta-estradiol; all-trans-retinoic acid; bisphenol A.
[Estradiol co-treated with Progesterone] results in increased expression of HOXA10 mRNA, [Estradiol co-treated with Progesterone] results in increased expression of HOXA10 protein
Estradiol inhibits the reaction [Fulvestrant results in increased expression of HOXA10 mRNA], Fulvestrant inhibits the reaction [Estradiol results in decreased expression of HOXA10 mRNA]
4-tert-octylphenol inhibits the reaction [Fulvestrant results in increased expression of HOXA10 mRNA], [Fulvestrant co-treated with 4-tert-octylphenol] results in decreased expression of HOXA10 mRNA
[Medroxyprogesterone Acetate co-treated with Estrogens] results in increased expression of HOXA10 mRNA, Mifepristone inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of HOXA10 mRNA]
Methoxychlor inhibits the reaction [Estradiol promotes the reaction [ESR1 protein binds to HOXA10 gene]], Methoxychlor promotes the reaction [ESR1 protein binds to HOXA10 gene]
4-tert-octylphenol inhibits the reaction [Fulvestrant results in increased expression of HOXA10 mRNA], [Fulvestrant co-treated with 4-tert-octylphenol] results in decreased expression of HOXA10 mRNA
[Estradiol co-treated with Progesterone] results in increased expression of HOXA10 mRNA, [Estradiol co-treated with Progesterone] results in increased expression of HOXA10 protein
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
